Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: purified talc; hyprolose; iron oxide yellow; ethanol absolute; purified water; diacetylated monoglycerides; magnesium stearate; light magnesium oxide; hypromellose phthalate; ethylcellulose; titanium dioxide; carnauba wax; mannitol - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: povidone; mannitol; sodium starch glycollate type a; diethyl phthalate; purified talc; magnesium stearate; hypromellose phthalate; light magnesium oxide; iron oxide red; titanium dioxide; ethylcellulose - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: povidone; mannitol; sodium starch glycollate type a; diethyl phthalate; purified talc; magnesium stearate; hypromellose phthalate; light magnesium oxide; iron oxide red; titanium dioxide; ethylcellulose - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: povidone; mannitol; sodium starch glycollate type a; diethyl phthalate; purified talc; magnesium stearate; hypromellose phthalate; light magnesium oxide; iron oxide red; titanium dioxide; ethylcellulose - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: sodium starch glycollate type a; diethyl phthalate; purified talc; povidone; titanium dioxide; iron oxide red; hypromellose phthalate; ethylcellulose; magnesium stearate; light magnesium oxide; mannitol - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: ethylcellulose; titanium dioxide; mannitol; crospovidone; magnesium stearate; iron oxide yellow; diacetylated monoglycerides; heavy magnesium oxide; light magnesium oxide; purified talc; hyprolose; hypromellose phthalate - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: hypromellose phthalate; purified water; titanium dioxide; ethanol absolute; light magnesium oxide; magnesium stearate; diacetylated monoglycerides; iron oxide yellow; carnauba wax; hyprolose; ethylcellulose; purified talc; mannitol - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: diethyl phthalate; mannitol; ethylcellulose; magnesium stearate; iron oxide yellow; povidone; sodium starch glycollate type a; hypromellose phthalate; titanium dioxide; purified talc; light magnesium oxide - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: titanium dioxide; povidone; magnesium stearate; hypromellose phthalate; purified talc; light magnesium oxide; sodium starch glycollate type a; diethyl phthalate; iron oxide yellow; mannitol; ethylcellulose - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: ethylcellulose; iron oxide yellow; sodium starch glycollate type a; light magnesium oxide; diethyl phthalate; magnesium stearate; titanium dioxide; hypromellose phthalate; mannitol; povidone; purified talc - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.